Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”

Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada

Clin Mol Hepatol. 2024;30(2):281-283. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0214

View: 1142 Download: 14

Letter to the Editor

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 1254 Download: 32

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 1552 Download: 108

Editorial

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2024;30(2):168-170. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0140

View: 1400 Download: 41 Crossref: 1

Correspondence

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(1):126-128. Published online November 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0500

View: 1186 Download: 35

Letter to the Editor

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 1362 Download: 72 Web of Science: 2 Crossref: 2

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 1685 Download: 45 Web of Science: 1 Crossref: 1

Review

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 5304 Download: 245 Web of Science: 10 Crossref: 11

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 4500 Download: 225 Web of Science: 11 Crossref: 14

Editorial

Adding to the confusion in more than just the name

Jacob George

Clin Mol Hepatol. 2023;29(4):973-976. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0367

View: 1479 Download: 63 Web of Science: 3 Crossref: 4

Special Review

Waiting for the changes after the adoption of steatotic liver disease

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):844-850. Published online September 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0291

View: 2148 Download: 161 Web of Science: 5 Crossref: 13

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Gi-Ae Kim, Joon Ho Moon, Won Kim

Clin Mol Hepatol. 2023;29(4):831-843. Published online August 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0277

View: 3628 Download: 342 Web of Science: 8 Crossref: 17

Editorial

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 2631 Download: 76 Web of Science: 2 Crossref: 3

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 2380 Download: 94 Web of Science: 2 Crossref: 1

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0086

View: 2641 Download: 113 Web of Science: 3 Crossref: 3

Review

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):320-331. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

View: 5021 Download: 339 Web of Science: 10 Crossref: 13

Original Article

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):841-850. Published online September 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0239

View: 6080 Download: 228 Web of Science: 62 Crossref: 71

Editorial

Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2022;28(4):802-805. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0249

View: 2561 Download: 74 Web of Science: 2 Crossref: 2

Review

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(4):725-738. Published online March 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0015

View: 4759 Download: 245 Web of Science: 7 Crossref: 10

Editorial

Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Byoung Seok Ye

Clin Mol Hepatol. 2022;28(3):481-482. Published online May 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0097

View: 2719 Download: 70 Web of Science: 1 Crossref: 2

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 4796 Download: 319 Web of Science: 6 Crossref: 6

Original Article

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study

Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae

Clin Mol Hepatol. 2022;28(2):196-206. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0371

View: 5444 Download: 205 Web of Science: 15 Crossref: 15

Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome

Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo

Clin Mol Hepatol. 2021;27(3):463-473. Published online February 15, 2021

DOI: https://doi.org/10.3350/cmh.2020.0351

View: 5252 Download: 164 Web of Science: 2 Crossref: 2

Review

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee

Clin Mol Hepatol. 2021;27(2):257-269. Published online March 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0067

View: 8501 Download: 428 Web of Science: 63 Crossref: 63

Editorial

Metabolic disease as a risk of hepatocellular carcinoma

Naoshi Nishida

Clin Mol Hepatol. 2021;27(1):87-90. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0302

View: 4759 Download: 106 Web of Science: 11 Crossref: 13

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try

Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan

Clin Mol Hepatol. 2021;27(1):83-86. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0298

View: 4737 Download: 157 Web of Science: 1 Crossref: 1

Review

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0137

View: 9784 Download: 476 Web of Science: 35 Crossref: 35

Application of transient elastography in nonalcoholic fatty liver disease

Xinrong Zhang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2020;26(2):128-141. Published online November 8, 2019

DOI: https://doi.org/10.3350/cmh.2019.0001n

View: 14050 Download: 563 Web of Science: 59 Crossref: 64

Original Article

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang

Clin Mol Hepatol. 2019;25(1):52-64. Published online October 23, 2018

DOI: https://doi.org/10.3350/cmh.2018.0040

View: 8477 Download: 338 Web of Science: 74 Crossref: 72

The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease

Goh Eun Chung, Donghee Kim, Min-Sun Kwak, Jong In Yang, Jeong Yoon Yim, Seon Hee Lim, Mustafa Itani

Clin Mol Hepatol. 2016;22(1):146-151. Published online March 28, 2016

DOI: https://doi.org/10.3350/cmh.2016.22.1.146

View: 10173 Download: 140 Web of Science: 48 Crossref: 46

1 | 2 |

Viewed By 5880	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5234	MAFLD: How is it different from NAFLD?
Viewed By 4950	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4033	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4018	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 137	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 104	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 82	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 71	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 63	MAFLD: How is it different from NAFLD?

Search